CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 503 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $71,594 | -34.9% | 1,345 | -16.7% | 0.00% | – |
Q1 2024 | $110,043 | -85.8% | 1,614 | -87.0% | 0.00% | -100.0% |
Q4 2023 | $775,927 | +114.9% | 12,395 | +124.5% | 0.00% | +100.0% |
Q3 2022 | $361,000 | +7.8% | 5,520 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $335,000 | -3.2% | 5,520 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $346,000 | -18.6% | 5,520 | -1.6% | 0.00% | 0.0% |
Q4 2021 | $425,000 | -33.9% | 5,609 | -2.4% | 0.00% | 0.0% |
Q3 2021 | $643,000 | -75.7% | 5,749 | -64.8% | 0.00% | -83.3% |
Q2 2021 | $2,643,000 | -29.6% | 16,324 | -47.0% | 0.01% | -33.3% |
Q1 2021 | $3,754,000 | +304.1% | 30,805 | +407.5% | 0.01% | +350.0% |
Q4 2020 | $929,000 | +76.3% | 6,070 | -3.7% | 0.00% | 0.0% |
Q3 2020 | $527,000 | +154.6% | 6,300 | +28.8% | 0.00% | +100.0% |
Q1 2020 | $207,000 | -22.5% | 4,890 | +11.4% | 0.00% | 0.0% |
Q4 2019 | $267,000 | +1060.9% | 4,390 | +1040.3% | 0.00% | – |
Q2 2018 | $23,000 | -4.2% | 385 | -26.7% | 0.00% | – |
Q1 2018 | $24,000 | – | 525 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |